Centauri Therapeutics appoints Dr. Debra Barker as Chief Medical Officer

July 8, 2025 | News Updates

  • Experienced clinical immunologist and global life science executive to support progression of lead candidate through the clinic
  • ABX-01 clinical candidate is an immunotherapeutic, based on proprietary Alphamer® platform and designed for treatment of Gram-negative bacterial infections

See attached press release

Related Posts

Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials

July 29, 2025 | News Updates
Read More about Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials
Pipettes

Centauri Therapeutics publishes proof-of-concept data demonstrating activity of a novel bifunctional immunotherapy against Gram-negative bacterial infections

June 10, 2025 | News
Read More about Centauri Therapeutics publishes proof-of-concept data demonstrating activity of a novel bifunctional immunotherapy against Gram-negative bacterial infections
Scientist in lab

Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections

March 4, 2025 | News
Read More about Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections